Avoro Capital Advisors 13F: Exits RARE Stake

Avoro Capital Advisors has fully exited its investment in RARE, selling all its 330,000 shares. This move leaves the fund with no remaining stake in the company, as reported in its latest 13F filing with the SEC, reflecting holdings as of the last reporting period.

What Changed in Avoro Capital Advisors' RARE Position

Avoro Capital Advisors cut its entire position in RARE, which previously stood at 330,000 shares. This represents a 100% reduction, leaving the fund with no shares in the company.

Other Institutional Activity in RARE

Several other institutional investors made changes to their RARE holdings. BlackRock, Inc. increased its stake by 668,044 shares, ending with approximately 7.3 million shares valued at $152.9 million. Vanguard Portfolio Management LLC initiated a new position with 5.4 million shares worth $112.8 million. State Street Corp added 718,395 shares, resulting in a total of about 5 million shares valued at $105.2 million. AQR Capital Management LLC significantly boosted its holdings by 3.2 million shares to reach 4.6 million shares, valued at $95.9 million. Meanwhile, RTW Investments, LP increased its position by 648,656 shares, holding a total of 3.6 million shares worth $76.4 million.

Ultragenyx Pharmaceutical Inc. Stock Up 67.8%

Shares of RARE are currently trading at $24.35. The stock has seen various institutional movements, which might influence investor sentiment. However, the current market cap, P/E ratio, and other financial metrics were not provided.

Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.

Recent insider activity at RARE includes several transactions. On June 1, 2026, Howard Horn, the CFO, sold 4,653 shares at $23.77 each as part of a planned sale. Shehnaaz Suliman sold 5,740 shares at $25.12 on May 18, 2026, also under a planned transaction. On May 14, 2026, Shehnaaz Suliman, Amrit Ray, and Michael Narachi each bought shares without a planned schedule, purchasing 14,058 shares, 7,751 shares, and 14,058 shares respectively, though the price per share was not disclosed.

Analysts Set New Price Targets

Analysts have maintained a range of ratings on RARE. On May 21, 2026, Cantor Fitzgerald maintained a buy rating with a $96 price target. Guggenheim and Barclays both upheld buy ratings with targets of $43. Wells Fargo set a buy rating with a $47 target on May 6, 2026. Conversely, Goldman Sachs downgraded the stock to hold with a $25 target on March 24, 2026. The consensus among analysts suggests a mixed outlook, with a variety of price targets and recommendations.

About RARE

RARE is a company operating in the biotechnology sector, focusing on developing treatments for rare diseases. Its innovative approach aims to address unmet medical needs, positioning itself as a leader in the biotech industry. The company is headquartered in the United States and continues to advance its pipeline of potential therapies.

Bottom Line

Avoro Capital Advisors' decision to sell its entire stake in RARE marks a significant shift in its investment strategy. With RARE's stock trading at $24.35, investors will be watching closely to see how the company's strategies and market conditions affect its performance. The 13F filing provides a historical perspective on Avoro's holdings and does not necessarily indicate current positions.